Cited by 216Parkinson's Disease Mechanisms and TreatmentsSulfur Compounds in BiologyLysosomal Storage Disorders Research

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

N-acetylcysteine Boosts Brain and Blood Glutathione in Gaucher and Parkinson Diseases

Open access

Holmay, Mary J., Terpstra, Melissa, Coles, Lisa D., Mishra, Usha, Ahlskog, Matthew, Öz, Gülin, Cloyd, James C., Tuite, Paul J.·2013·Clinical Neuropharmacology

DOI 10.1097/wnf.0b013e31829ae713PMC PMC3934795

Open this paper in CoChat — free account

Abstract

OBJECTIVE: This study aimed to determine if the antioxidant N-acetylcysteine (NAC) is able to alter peripheral and central redox capabilities in patients with Parkinson disease (PD) or Gaucher disease (GD). METHODS: The study included nondemented adult subjects: 3 with PD, 3 with GD, and 3 healthy controls. Baseline brain glutathione (GSH) concentrations were measured using 7-T magnetic resonance spectroscopy (MRS). Baseline blood reduced-to-oxidized GSH ratios were determined for each subject. Brain GSH concentrations and blood redox ratios were then determined during and at specified time points after a single, 150-mg/kg NAC infusion. RESULTS: N-acetylcysteine increased blood GSH redox ratios in those with PD and GD and healthy controls, which was followed by an increase in brain GSH concentrations in all subjects. CONCLUSIONS: This is the first demonstration that with MRS, it is possible to directly measure and monitor increases in brain GSH levels in the human brain in response to a single, intravenous administration of NAC. This work shows the potential utility of MRS monitoring, which could assist in determining dosing regimens for clinical trials of this potentially useful antioxidant therapy for PD disease, GD, and other neurodegenerative disorders.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1097/wnf.0b013e31829ae713

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
Oxidative stress in Parkinson's disease
Jenner, P. (2003) · Annals of Neurology · doi:10.1002/ana.10483 · Cited by 2,053
Metabolism and functions of glutathione in brain
Dringen, R. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00060-x · Cited by 1,702
Proton NMR chemical shifts and coupling constants for brain metabolites
Govindaraju, V., Young, K., & Maudsley, A. A. (2000) · NMR in Biomedicine · doi:10.1002/1099-1492(200005)13:3 · Cited by 1,695
Automatic quantitation of localized in vivo1H spectra with LCModel
Provencher, S. W. (2001) · NMR in Biomedicine · doi:10.1002/nbm.698 · Cited by 1,640
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia
Sian, J., Dexter, D. T., Lees, A. J., Daniel, S., Agid, Y., Javoy‐Agid, F., Jenner, P., & Marsden, C. D. (1994) · Annals of Neurology · doi:10.1002/ana.410360305 · Cited by 1,161 · cited 4×
“In this study, we focused on the occipital cortex rather than the substantia nigra, where a GSH deficit has been detected postmortem in PD.(1) Because of challenges associated with MRS in the substantia nigra in humans, including its location, very small size (limiting signal-to-noise ratio), and high iron content (gi…”
BackgroundInfluential
Oxidatively modified proteins in aging and disease1, 2 1Guest Editor: Earl Stadtman 2This article is part of a series of reviews on “Oxidatively Modified Proteins in Aging and Disease” The full list of papers may be found on the homepage of the journal
Beal, M. F. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00780-3 · Cited by 763
Neuronal glutathione deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse
Aoyama, K., Suh, S. W., Hamby, A. M., Liu, J., Chan, W. Y., Chen, Y., & Swanson, R. A. (2006) · Nature Neuroscience · doi:10.1038/nn1609 · Cited by 484
Analysis of macromolecule resonances in 1 H NMR spectra of human brain
Behar, K. L., Rothman, D. L., Spencer, D. D., & Petroff, O. A. C. (1994) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910320304 · Cited by 468 · cited 1×
“680 seconds).(24) Metabolites quantified with Cramér-Rao lower bounds (estimated error of the metabolite quantification) greater than 50% or correlation coefficient less than −0.”
Method
N-Acetylcysteine, a Glutamate Modulator, in the Treatment of Trichotillomania: A Double-blind, Placebo-Controlled Study
Grant, J. E., Odlaug, B. L., & Won Kim, S. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.60 · Cited by 424 · cited 1×
“There are reports of positive effects of oral NAC in disorders with central nervous system involvement.(29,30) Future studies are necessary to determine if oral NAC affects brain [GSH] and if so, to establish optimal dosage regimens to attain sustained elevation of brain [GSH] with repeated dosing.”
Background

Show all 29 references

Sorted by citations

Items 101–200 of 215

The neuroprotective effects of N-acetylcysteine in psychiatric and neurodegenerative disorders: From modulation of glutamatergic transmission to restoration of synaptic plasticity
Chakraborty, S., Rao, S., & Tripathi, S. J. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110527 · Cited by 25
A rapid colorimetric method for determining glutathione based on the reaction between cobalt oxyhydroxide nanosheets and 3,3′,5,5′-Tetramethylbenzidine
Yuan, L., Guo, W., Fu, Y., Zhang, Z., Wang, P., & Wang, J. (2020) · Microchemical Journal · doi:10.1016/j.microc.2020.105639 · Cited by 23
Animal models and high field imaging and spectroscopy
Öz, G., Tkáč, I., & Uǧurbil, K. (2013) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2013.15.3/goz · Cited by 23
“The ability to measure an extended “neurochemical profile” increases the likelihood of identifying underlying processes on the molecular level, to detect disease-specific metabolic signatures and to directly assess mechanisms of drug actions, eg, by measuring endogenous antioxidant levels to assess effects of antioxid…”
BackgroundSelf-citation
Improved oxidative status in major abdominal surgery patients after N-acetyl cystein supplementation
Kuyumcu, A., Akyol, A., Büyüktuncer, Z., Özmen, M. M., & Besler, H. T. (2015) · Nutrition Journal · doi:10.1186/1475-2891-14-4 · Cited by 23
“The current study demonstrated a profound increase in GSH levels in the NAC treated group, as in other studies [13,36].”
Result
The molecular mechanism of ferroptosis and its relationship with Parkinson's disease
Su, Y. R., Jiao, Y., Cai, S., Xu, Y., Wang, Q., & Chen, X. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.110991 · Cited by 23
“N-acetylcysteine (NAC) and GSH have improved the clinical symptoms of PD patients by increasing their GSH levels in clinical trials (Monti et al., 2019; Holmay et al., 2013; Mischley et al., 2017).”
NAC and Vitamin D Improve CNS and Plasma Oxidative Stress in Neonatal HIE and Are Associated with Favorable Long-Term Outcomes
Jenkins, D., Moss, H. G., Brown, T. R., Yazdani, M., Thayyil, S., Montaldo, P., Vento, M., Kuligowski, J., Wagner, C. L., Hollis, B. W., et al. (2021) · Antioxidants · doi:10.3390/antiox10091344 · Cited by 22
From regenerative strategies to pharmacological approaches: can we fine-tune treatment for Parkinson's disease?
Caridade-Silva, R., Domingues, H. S., Salgado, A. J., & Teixeira, F. G. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.324827 · Cited by 22
“In fact, recent controlled and randomized clinical trials have demonstrated that intravenous administration of NAC increased blood redox rations of glutathione (Holmay et al., 2013) and may positively affect the dopaminergic system in patients with PD (Monti et al., 2019, 2016).”
Background
Ongoing oxidative stress in individuals with post-acute sequelae of COVID-19
Saleh, M. G., Chang, L., Liang, H., Ryan, M. C., Cunningham, E. P., Garner, J. M., Wilson, E. M. P., Levine, A. R., Kottilil, S., & Ernst, T. (2022) · NeuroImmune Pharmacology and Therapeutics · doi:10.1515/nipt-2022-0006 · Cited by 21
“Since higher levels of the antioxidantGSHare essential for reducing ROS, the administration of N-acetylcysteine (NAC) [9], which is a cysteine precursor for GSH biosynthesis, might be useful for enhancing GSH levels in individuals with PASC [10].”
Background
Neuropsychiatric Manifestations of COVID-19 Disease and Post COVID Syndrome: The Role of N-acetylcysteine and Acetyl-L-carnitine
Barlattani, T., Celenza, G., Cavatassi, A., Minutillo, F., Socci, V., Pinci, C., Santini, R., & Pacitti, F. (2024) · Current Neuropharmacology · doi:10.2174/011570159x343115241030094848 · Cited by 20
“The mGluR3 receptor, predominantly located in astrocytes, is involved in glutamate uptake and synaptic modulation, thus protecting against neuro excitotoxicity [69, 195, 196].”
Nutraceuticals as Modulators of Autophagy: Relevance in Parkinson’s Disease
Rakowski, M., Lekki-Porębski, S. A., & Grzelak, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073625 · Cited by 20
Natural variation in age-related dopamine neuron degeneration is glutathione dependent and linked to life span
Coleman, C. R., Pallos, J., Arreola-Bustos, A., Wang, L., Raftery, D., Promislow, D., & Martin, I. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2403450121 · Cited by 20
“Intravenous NAC admin istration boosts brain total glutathione levels in PD patients ( 94 ) and a recent clinical trial showed that combined intravenous and oral administration of NAC may have a beneficial effect in PD ( 95 ).”
In Vivo NMR Studies of the Brain with Hereditary or Acquired Metabolic Disorders
Sherry, E. B., Lee, P., & Choi, I.-Y. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1772-1 · Cited by 22
“(1)H MRS of patients with Gaucher disease showed an improvement in brain GSH levels with administration of N-acetylcysteine, a membrane-permeable cysteine precursor, which serves as the rate limiting substrate for GSH biosynthesis [304].”
Background
Prevention of hypoglycemia-induced hippocampal neuronal death by N-acetyl-l-cysteine (NAC)
Kho, A. R., Choi, B. Y., Kim, J. H., Lee, S. H., Hong, D. K., Lee, S. H., Jeong, J. H., Sohn, M., & Suh, S. W. (2016) · Amino Acids · doi:10.1007/s00726-016-2370-5 · Cited by 20
N-acetylcysteine Provides Cytoprotection in Murine Oligodendrocytes through Heme Oxygenase-1 Activity
Zhou, J., Terluk, M. R., Basso, L. M., Mishra, U. R., Orchard, P. J., Cloyd, J. C., Schröder, H., & Kartha, R. V. (2020) · Biomedicines · doi:10.3390/biomedicines8080240 · Cited by 20
“Previously we have shown that NAC, an indirect source for GSH, can also increase brain GSH when administered intravenously [12,23].”
BackgroundSelf-citation
N-acetyl cysteine in the treatment of cannabis use disorder: A systematic review of clinical trials
Sharma, R., Tikka, S. K., Bhute, A. R., & Bastia, B. K. (2022) · Addictive Behaviors · doi:10.1016/j.addbeh.2022.107283 · Cited by 19
The Central Nervous System Modulatory Activities of N-Acetylcysteine: A Synthesis of Two Decades of Evidence
Cherneva, D. I., Kehayova, G. K., Dimitrova, S., & Dragomanova, S. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47090710 · Cited by 23
“Holmay et al. (2013) examined the impact of NAC on both peripheral and central redox capacity in a cohort of nine non-demented adults, including individuals with PD, Gaucher disease, and healthy controls [35].”
Pharmacological elevation of glutathione inhibits status epilepticus-induced neuroinflammation and oxidative injury
Liang, L., Hari, A. S., Day, B. J., & Patel, M. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103168 · Cited by 17
Protective Effect of γ-mangostin Isolated from the Peel of Garcinia mangostana against Glutamate-Induced Cytotoxicity in HT22 Hippocampal Neuronal Cells
Baek, J. Y., Jung, K., Kim, Y., Kim, H., Kang, K. S., & Chin, Y. (2021) · Biomolecules · doi:10.3390/biom11020170 · Cited by 17
Multinuclear Magnetic Resonance Spectroscopy at Ultra-High-Field: Assessing Human Cerebral Metabolism in Healthy and Diseased States
Veeraiah, P., & Jansen, J. F. A. (2023) · Metabolites · doi:10.3390/metabo13040577 · Cited by 16
Niacin for Parkinson's disease
Seamon, M., Purohit, S. B., Giri, B., Baban, B., Morgan, J. C., Chong, R. K. Y., & Wakade, C. G. (2019) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12553 · Cited by 16
α-synucleinopathy exerts sex-dimorphic effects on the multipurpose DNA repair/redox protein APE1 in mice and humans
Miner, K. M., Jamenis, A. S., Bhatia, T. N., Clark, R. N., Rajasundaram, D., Sauvaigo, S., Mason, D. M., Posimo, J. M., Abraham, N., DeMarco, B. A., et al. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102307 · Cited by 14
Investigation of the therapeutic potential of N-acetyl cysteine and the tools used to define nigrostriatal degeneration in vivo
Nouraei, N., Zarger, L., Weilnau, J. N., Han, J., Mason, D. M., & Leak, R. K. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.02.010 · Cited by 15
“Recent studies have shown that NAC increases glutathione levels in the brain of patients with Parkinson's disease, supporting the view that NAC can indeed cross the blood-brain barrier (Holmay et al., 2013; Katz et al., 2015).”
Background
A pilot study of oxidative pathways in MS fatigue: randomized trial of N‐acetyl cysteine
Krysko, K. M., Bischof, A., Nourbakhsh, B., Henry, R. G., Revirajan, N., Manguinao, M., Nguyen, K., Akula, A. V., Li, Y., & Waubant, E. L. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51325 · Cited by 15
“A concealed randomized allocation schedule was generated by a team member not participating in the assessment of participants, and this was sent to the study pharmacy, which prepared and distributed blinded study drug to the UCSF research coordinator based on the randomization schedule.”
Background
Cerebellar neurochemical alterations in spinocerebellar ataxia type 14 appear to include glutathione deficiency
Doss, S., Rinnenthal, J. L., Schmitz‐Hübsch, T., Brandt, A. U., Papazoglou, S., Lux, S., Maul, S., Wuerfel, J. T., Endres, M., Klockgether, T., et al. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7788-2 · Cited by 16
“Nevertheless, in vivo MR spectroscopy in a Parkinson’s disease patient captured the reversion of GSH decrease after treatment with the precursor N-acetylcysteine [34] demonstrating its usefulness to monitor potential therapeutic interventions.”
Background
Mitochondrial Dysfunction in Aging: Future Therapies and Precision Medicine Approaches
Jia, L., Wei, Z., Luoqian, J., Wang, X., & Huang, C. (2025) · MedComm – Future Medicine · doi:10.1002/mef2.70026 · Cited by 14
Targeting the Cysteine Redox Proteome in Parkinson’s Disease: The Role of Glutathione Precursors and Beyond
Martínez, M. (2023) · Antioxidants · doi:10.3390/antiox12071373 · Cited by 14
“A unique intravenous dose of NAC augmented the blood GSH/GSSG ratio and total GSH in the brain, showing a positive direct correlation between the blood ratio and brain GSH concentrations [205].”
Background
N -acetylcysteine increases dopamine release and prevents the deleterious effects of 6-OHDA on the expression of VMAT2, α-synuclein, and tyrosine hydroxylase
El‐Habta, R., af Bjerkén, S., & Virel, A. (2024) · Neurological Research · doi:10.1080/01616412.2024.2325312 · Cited by 15
“In Parkinsonian patients, NAC has shown to be able to cross the blood-brain-barrier, restore brain glutathione levels [19], and to have a beneficial impact on the nigrostriatal dopaminergic system [17,20].”
Background
Attenuation of toluene-induced brain stimulation reward enhancement and behavioral disturbances by N-acetylcysteine in mice
Wu, C., Tsai, Y.-L., Hsieh, C.-P., Wang, T. C., Chan, M., & Chen, H. (2018) · Toxicology · doi:10.1016/j.tox.2018.06.011 · Cited by 14
Aging at the Crossroads of Cuproptosis and Ferroptosis: From Molecular Pathways to Age-Related Pathologies and Therapeutic Perspectives
Gromadzka, G., Tarnacka, B., & Cieślik, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27010522 · Cited by 19
Antioxidative NAC-Loaded Silk Nanoparticles with Opening Mucosal Tight Junctions for Nasal Drug Delivery: An In Vitro and In Vivo Study
Chung, T., Wu, T.-Y., Siah, Z.-Y., & Liu, D.-Z. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061288 · Cited by 13
“N-Acetyl-L-cysteine (NAC) is a membrane-permeable cysteine precursor that is a ratelimiting substrate for GSH biosynthesis and a free radical scavenger or an antioxidant that is involved in the intracellular and extracellular detoxification of reactive oxygen species in the brain [22].”
Background
Iron- and Neuromelanin-Weighted Neuroimaging to Study Mitochondrial Dysfunction in Patients with Parkinson’s Disease
Pizarro-Galleguillos, B., Kunert, L., Brüggemann, N., & Prasuhn, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213678 · Cited by 13
A comparative study of posterior cingulate metabolism in patients with mild cognitive impairment due to Parkinson's disease or Alzheimer's disease
Huang, M., Yu, H., Cai, X., Zhang, Y., Pu, W., & Gao, B. (2023) · Scientific Reports · doi:10.1038/s41598-023-41569-5 · Cited by 13
Effect of Pharmacological and Neurostimulation Interventions for Cognitive Domains in Patients with Bipolar Disorder: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
Chen, W., Liu, H., Cheng, Y., Li, H., Huang, C., Ding, Y., Huang, M., Chiu, C., Tu, Y., & Kuo, P. (2021) · Clinical Epidemiology · doi:10.2147/clep.s335584 · Cited by 14
Contributions and Limitations of Mitochondria-Targeted and Non-Targeted Antioxidants in the Treatment of Parkinsonism: an Updated Review
Banerjee, P., Saha, I., Sarkar, D., & Maiti, A. K. (2022) · Neurotoxicity Research · doi:10.1007/s12640-022-00501-x · Cited by 13
“In a clinical trial involving Parkinson’s and Gaucher’s disease patients, a single intravenous infusion of 150 mg/kg NAC resulted in elevated GSH concentration in all the subjects though the result was short lasting with GSH concentration returning to basal levels after 2 h (Holmay et al. 2013).”
Background
N-Acetylcysteine Treatment May Compensate Motor Impairments through Dopaminergic Transmission Modulation in a Striatal 6-Hydroxydopamine Parkinson’s Disease Rat Model
Caridade-Silva, R., Araújo, B., Martins‐Macedo, J., & Teixeira, F. G. (2023) · Antioxidants · doi:10.3390/antiox12061257 · Cited by 12
“Indeed, reports have suggested NAC as a booster of GSH synthesis in PD, increasing its levels in both animals’ and patients’ brains [32,66,67].”
Background
Magnetic resonance spectroscopy studies of substance use disorders: Current landscape and potential future directions
Kohut, S. J., & Kaufman, M. J. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.173090 · Cited by 12
“N-acetylcysteine (NAC) is a GSH precursor that when infused increases human brain GSH as measured with 1H-MRS (Holmay et al., 2013).”
Method
Synthesis and characterization of brain penetrant prodrug of neuroprotective D-264: Potential therapeutic application in the treatment of Parkinson’s disease
Dholkawala, F. S., Voshavar, C., & Dutta, A. K. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.03.017 · Cited by 11
Glutathione Therapy in Diseases: Challenges and Potential Solutions for Therapeutic Advancement
Dehkordi, H. T., & Ghasemi, S. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230818142831 · Cited by 10
L-Cysteine: A promising nutritional supplement for alleviating anxiety disorders
Liu, R., Song, D., Zhang, Y., Gong, H., Jin, Y., Wang, X., Jiang, Y., Yan, Y.-X., Lu, B.-N., Wu, Y., et al. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.07.038 · Cited by 11
Improvement of Oxidative and Metabolic Parameters by Cellfood Administration in Patients Affected by Neurodegenerative Diseases on Chelation Treatment
Fulgenzi, A., Giuseppe, R. D., Bamonti, F., & Ferrero, M. E. (2014) · BioMed Research International · doi:10.1155/2014/281510 · Cited by 10
“[7] Holmay MJ, Terpstra M, Coles LD, Mishra U, Ahlskog M, Oz G, et al.”
BackgroundResult
N-acetyl cysteine administration affects cerebral blood flow as measured by arterial spin labeling MRI in patients with multiple sclerosis
Shahrampour, S., Heholt, J., Wang, A. A., Vedaei, F., Mohamed, F. B., Alizadeh, M., Wang, Z., Zabrecky, G. P., Wintering, N., Bazzan, A. J., et al. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e07615 · Cited by 10
Neurotransmitter imbalance, glutathione depletion and concomitant susceptibility increase in Parkinson’s disease
Yan, S., Duan, B., Li, Y., Zhu, H., Shi, Z., Zhang, X., Qin, Y., & Zhu, W. (2025) · NeuroImage Clinical · doi:10.1016/j.nicl.2025.103740 · Cited by 9
“Both blood measures of GSH and cerebral GSH levels by MRS were shown to be decreased in PD, providing a possible early PD biomarker to reflect high oxidative damage (Holmay et al., 2013; Mischley et al., 2016).”
Metabolic reprogramming and signalling networks in microglial activation: Implications for neurodegeneration
El-Hamri, M.-A., & Abboussi, O. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103138 · Cited by 9
Glutathione: pharmacological aspects and implications for clinical use
Novelli, A., & Bianchetti, A. (2022) · Geriatric Care · doi:10.4081/gc.2022.10390 · Cited by 9
Intracellular Accumulation of α-Synuclein Aggregates Promotes S-Nitrosylation of MAP1A Leading to Decreased NMDAR-Evoked Calcium Influx and Loss of Mature Synaptic Spines
Hallam, R. D., Buchner-Duby, B., Stykel, M. G., Coackley, C. L., & Ryan, S. D. (2022) · Journal of Neuroscience · doi:10.1523/jneurosci.0074-22.2022 · Cited by 9
Oxidative Stress in Psychiatric Disorders
Fung, L. K., & Hardan, A. Y. (2018) · Springer eBooks · doi:10.1007/978-981-10-5311-5_4 · Cited by 9
Ultra-High-Field Imaging of the Pediatric Brain and Spinal Cord
Deelchand, D. K., Ho, M., & Nestrašil, I. (2021) · Magnetic Resonance Imaging Clinics of North America · doi:10.1016/j.mric.2021.06.013 · Cited by 9
Proceedings of the workshop on Cerebellum, Basal Ganglia and Cortical Connections Unmasked in Health and Disorder Held in Brno, Czech Republic, October 17th, 2013
Bareš, M., Apps, R., Kikinis, Z., Timmann, D., Öz, G., Ashe, J., Loft, M. S. E., Koutsikou, S., Cerminara, N. L., Bushara, K. O., et al. (2014) · The Cerebellum · doi:10.1007/s12311-014-0595-y · Cited by 9
“Another recent study focused on a potentially useful antioxidant therapy in PD. Reductions in the levels of the major antioxidant glutathione (GSH) were reported in PD [62], indicating the involvement of oxidative stress in the pathophysiology of the disease.”
Self-citation
Nutraceuticals and Other Natural Products in Parkinson’s Disease Therapy
Mythri, R. B., Joshi, A. K. R., & Bharath, M. M. S. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-411462-3.00044-8 · Cited by 9
Assessment of the Precision in Measuring Glutathione at 3 T With a MEGA‐PRESS Sequence in Primary Motor Cortex and Occipital Cortex
Anton, A., Mead, R. J., Shaw, P. J., Edden, R. A. E., Bigley, J., Jenkins, T. M., Wild, J. M., Hoggard, N., & Wilkinson, I. D. (2021) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.27842 · Cited by 8
Identifying Biological Signatures of N-Acetylcysteine for Non-Suicidal Self-Injury in Adolescents and Young Adults
Sahasrabudhe, S. A., Silamongkol, T., Park, Y. W., Colette, A. A., Eberly, L. E., Klimes‐Dougan, B., Coles, L. D., Öz, G., Mueller, B. A., Kartha, R. V., et al. (2021) · Journal of Psychiatry and Brain Science · doi:10.20900/jpbs.20210007 · Cited by 8
“%) as measured by MRS [28].”
BackgroundMethodInfluentialSelf-citation
Efforts Towards Repurposing of Antioxidant Drugs and Active Compounds for Multiple Sclerosis Control
Theodosis‐Nobelos, P., & Rekka, E. A. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03821-8 · Cited by 8
“Markedly increased improvement of clinical scores, inflammatory cytokine release and oxidative markers reduction in the brain have been recorded in EAE model with GSH increase in the brain being one important factor [68].”
Background
Opposite in vivo effects of agents that stimulate or inhibit the glutamate/cysteine exchanger system on the inhibition of hippocampal LTP by Aß
Zhang, D., Jin, B., Ondrejčák, T., & Rowan, M. J. (2016) · Hippocampus · doi:10.1002/hipo.22667 · Cited by 8
“In agreement with a critical role for GSH as a protective factor against the harmful synaptic effects of Aß, the system x2c activator NAC prevented the inhibition of LTP. NAC has been found to increase GSH synthesis in brain both directly and indirectly (Holmay et al., 2013; Zhou et al., 2015).”
Background
Antioxidant therapy in inborn metabolic diseases
Heimes, F., Berendes, L.-S., Hannibal, L., & Park, J. H. (2025) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2025.109176 · Cited by 7
Metabolomics comparison of metabolites and functional pathways in the SH-SY5Y cell model of Parkinson's disease under PEMF exposure
Zhu, L.-N., Chen, D., & He, C. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26540 · Cited by 7
“An increasing number of studies have reported markedly decreased GSH levels and GSH/GSSG ratios in both the brain tissues and blood of PD patients [34] [ – ] [37].”
Background
Milk intake enhances cerebral antioxidant (glutathione) concentration in older adults: A randomized controlled intervention study
Choi, I.-Y., Taylor, M., Lee, P., Hayek, S. A., Bechtel, M. D., Hamilton‐Reeves, J. M., Spaeth, K. R., Adany, P., & Sullivan, D. K. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.811650 · Cited by 7
“For example, a small study with N-acetylcysteine (NAC) infusion reported acute increases in brain GSH concentrations in three healthy older adults (35), while oral doses of NAC have been ineffective (36).”
Background
A pilot study to assess the effect of acute exercise on brain glutathione
Rai, S., Chowdhury, A., Reniers, R. L. E. P., Wood, S. J., Lucas, S. J. E., & Aldred, S. (2017) · Free Radical Research · doi:10.1080/10715762.2017.1411594 · Cited by 8
Parkinson’s Disease: Insights from Drosophila Model
Ayajuddin, M., Das, A., Phom, L., Modi, P., Chaurasia, R., Koza, Z., Thepa, A., Jamir, N., Singh, P. R., Longkumer, S., et al. (2018) · InTech eBooks · doi:10.5772/intechopen.72021 · Cited by 7
N-acetylcysteine for Parkinson’s disease: a translational systematic review of mechanistic and early clinical data
Mohammad, A., Ibrahim, M., Akram, M., Mohsin, H., Imran, M. T., & Alizai, H. N. K. (2025) · Neurodegenerative Disease Management · doi:10.1080/17582024.2025.2563489 · Cited by 6
Glutathione in HIV-Associated Neurocognitive Disorders
Erdos, T., Masuda, M., & Venketaraman, V. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46060330 · Cited by 7
Ferroptosis: a novel pathogenesis and therapeutic strategies for Parkinson disease: A review
Jiao, D., Yang, Y., Wang, K., & Wang, Y. (2025) · Medicine · doi:10.1097/md.0000000000041218 · Cited by 8
“[62,63] In a clinical trial of 42 patients with PD, participants were randomized into 2 groups; the treat-ment group received 50 mg/kg NAC intravenously weekly plus 500 mg NAC orally twice a day for 3 months, and the control group received only standard treatment.”
N-Acetylcysteine in Neurological Disorders: A Systematic Review of Clinical and Translational Evidence Across Seven Disorders
Mindreanu, R., Chiş, I. C., Sevastre-Berghian, A., Login, C., Stan, A., Stan, T., Clichici, S. V., & Suciu, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073076 · Cited by 5
Therapeutic Strategies in Neurodegenerative Diseases
Anderson, K. M., & Mosley, R. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-44022-4_42 · Cited by 5
Unlocking the link: how hippocampal glutathione–glutamate coupling predicts cognitive impairment in multiple sclerosis patients
Li, F., Zong, W., Xin, C., Ren, F., Li, N., Li, H., Xiao, L., Wu, L., Dai, Z., Chen, W., et al. (2023) · Cerebral Cortex · doi:10.1093/cercor/bhad400 · Cited by 5
N-acetylcysteine prevents cisplatin-induced cognitive impairments in an ovarian cancer rat model
Lomeli, N., Pearre, D. C., Lepe, J. J., Argueta, D. A., Arellano, M. A., Ricks‐Oddie, J., Gupta, K., & Bota, D. A. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217405 · Cited by 7
Inflammation: Role in Parkinson's Disease and Target for Therapy
Flood, P. M., Arbabzada, N., & Sharma, M. (2016) · InTech eBooks · doi:10.5772/63164 · Cited by 5
“Recently, a clinical trial with NAC intravenous infusion concludes that NAC enhances the level of glutathione (a potent antioxidant) in blood and brain in PD patients [141].”
Background
Examination of oxidative stress and glutamate as potential mechanisms of N-acetylcysteine in the treatment of non-suicidal self-injury in young people assigned female at birth: randomised trial
Papke, V., Klimes‐Dougan, B., Sahasrabudhe, S. A., Mueller, B. A., Park, Y. W., Öz, G., Eberly, L. E., DiMaggio-Potter, M. E., Kartha, R. V., Cloyd, J. C., et al. (2025) · BJPsych Open · doi:10.1192/bjo.2025.10839 · Cited by 4
“First, NAC has been shown to boost glutathione (GSH), the primary antioxidant in the blood 22 and brain 23,24 in humans.”
Self-citation
When Pathways Converge: Iron, Lipid Peroxidation, and α‐Synuclein in Ferroptosis‐Driven Dopaminergic Neurodegeneration
Sperlich, C. L., Stockwell, B. R., & Farina, M. (2026) · Journal of Neurochemistry · doi:10.1111/jnc.70438 · Cited by 5
The irony of Parkinson's disease: Converging mechanisms of redox imbalance and ferroptosis
Cooke, L., Rocha, E. M., Maio, R. D., Straub, A. C., & Fazzari, M. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104239 · Cited by 4
“In clinical trials, NAC has successfully increased both systemic and brain GSH levels [57,58].”
Combination Supplement Therapy: A New Frontier in Treatment of Neurodegenerative Diseases
Shtilbans, A. (2025) · Journal of Nutrition · doi:10.1016/j.tjnut.2025.07.004 · Cited by 3
An injectable hydrogel containing N -acetylglycine for the treatment of Gaucher disease
Pradhan, L., Manna, S., Yadav, A. J., Bajrang, B., Chakraborty, D., Bhagat, K., Tripathi, S., Parmar, A. S., Padhi, A. K., & Mukherjee, S. (2025) · RSC Advances · doi:10.1039/d5ra04610f · Cited by 3
“46,47 As expected, a signi  cant reduction in GCase activity was observed in cells transfected with siRNA compared to untreated cells (Fig.”
Translational and clinical pharmacology considerations in drug repurposing for X‐linked adrenoleukodystrophy—A rare peroxisomal disorder
Tieu, J., Sahasrabudhe, S. A., Orchard, P. J., Cloyd, J. C., & Kartha, R. V. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15090 · Cited by 3
Self-citation
RETRACTED ARTICLE: Effect of N-acetyl cysteine (NAC) supplementation on positive and negative syndrome scale in schizophrenia: a systematic review and meta-analysis of randomised controlled trials
Ghaderi, A., Bussu, A., Tsang, C., & Jafarnejad, S. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2595-1 · Cited by 3
Retracted
Comprehensive lipidomics reveal Rotenone exposure induces redox-driven lipid droplet accumulation, systemic lipidome perturbation and differential metabolic prioritization linked to Parkinson’s disease
Tiwari, A., Rathor, P., Patel, R. P., Jha, P. K., Birse, N., & Ch, R. (2026) · NeuroToxicology · doi:10.1016/j.neuro.2026.103425 · Cited by 5
The role of N-acetylcysteine and glutathione in the management of Parkinson’s disease: a systematic review of oxidative biomarkers and clinical outcomes
Mohammed, I., Nankya, Y., Hong, U. T., Kan, A., Abdelhafid, A. M., & Latunde-Dada, G. O. (2026) · Amino Acids · doi:10.1007/s00726-026-03513-5 · Cited by 2
“NAC was administered intravenously (IV) at 150 mg/ kg (Holmay et al. 2013) and orally in doses ranging from 7 mg/kg to 6000 mg/day (Katz et al. 2015; Coles et al. 2018; Monti et al. 2016, 2019).”
Influential
Population Pharmacokinetic Model of N‐Acetylcysteine During Periods of Recurrent Hypoglycemia in Healthy Volunteers
Fayed, M. S., Brooks, J., Seaquist, E. R., Kumar, A. F., Moheet, A. A., Eberly, L. E., Mishra, U. R., & Coles, L. D. (2023) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1338 · Cited by 2
“8,17 This study demonstrated that NAC is rapidly biotrans-formed to CYS in an NAC concentration-dependent manner, this is not seen in the placebo infusions, where CYS concentrations were relatively unchanged with time.”
BackgroundSelf-citation
Changes in Resting-State Functional Connectivity and Cognitive-Affective Symptoms in Patients With Post-Concussion Syndrome Treated With N-Acetyl Cysteine
Monti, D., Vedaei, F., Zabrecky, G. P., Alizadeh, M., Wintering, N., Bazzan, A. J., Mohamed, F. B., & Newberg, A. B. (2024) · Journal of Head Trauma Rehabilitation · doi:10.1097/htr.0000000000000976 · Cited by 3
“27 NAC is an antioxidant and precursor to glutathione, which has unique antioxidant and other properties of its own.”
Development of In Vitro Parkinson's Disease Model Mediated by MPP + and α‐Synuclein Using Wharton's Jelly Mesenchymal Stem Cells
Gamit, N., Patil, M., Soumya, B. S., Dharmarajan, A., & Warrier, S. R. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70299 · Cited by 2
Oral N-Acetyl Cysteine Administration Improved Oxidative Status in Medical Radiation Workers
El-Eneen, M. A., Morsi, M. I., & Soula, M. (2020) · Arab Journal of Nuclear Sciences and Applications · doi:10.21608/ajnsa.2020.17667.1279 · Cited by 2
Single voxel magnetic resonance spectroscopy: principles and applications
Tkáč, I., & Öz, G. (2021) · Advances in magnetic resonance technology and applications · doi:10.1016/b978-0-12-822479-3.00050-6 · Cited by 1
Self-citation
Are glutathionylated aldehyde reductases the missing piece of the “catecholaldehyde hypothesis” in Parkinson's disease? A medical hypothesis concerning the detoxification of 4-hydroxynonenal (HNE) and 3,4-dihydroxyphenylacetaldehyde (DOPAL)
Rotondo, R., Russo, M., Iacovelli, F., Calabrese, V., de Iure, A., Gaglione, M., Leonardi, L., Cocorocchia, G., Stocchi, F., Stocchi, V., et al. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104060 · Cited by 1
“Building on these findings, combined treatment with MAOIs and NAC in preclinical models further enhances DOPAL suppression and mitigates oxidative stress [67], likely through NAC's ability to cross the blood – brain barrier and restore intracellular glutathione [72,73].”
In vitro effect of N-acetyl-L-cysteine on glutathione and sulfhydryl levels in X-linked adrenoleukodystrophy patients
Marchetti, D. P., Donida, B., Deon, M., Jacques, C. E. D., Jardim, L. B., & Vargas, C. R. (2017) · Clinical & Biomedical Research · doi:10.4322/2357-9730.69868 · Cited by 1
Application of N-Acetylcysteine in Neurological Disorders
Shahripour, R., Maleki, A. H. Z., & Alexandrov, A. V. (2018) · Springer eBooks · doi:10.1007/978-981-10-5311-5_11 · Cited by 1
Parkinson’s Disease: Possible Mechanisms for Nutritional Approaches
Cherpak-Castagna, C. E., & Lare, S. J. V. (2020) · Journal of Restorative Medicine · doi:10.14200/jrm.2020.0104 · Cited by 1
Role of dietary antioxidants and redox status in Parkinson's disease
Amani, R., & Mehrabani, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-89834-8.00048-9 · Cited by 1
Nutritional Supplementation, Diet, and Genetics and Their Impact on Parkinson’s Disease (PD), a Review of Studies
Petrosino, S. P. (2014) · Journal of Nutritional Health & Food Engineering · doi:10.15406/jnhfe.2014.01.00038 · Cited by 1
“Thus MRS can be used in the establishment of dose regimens for clinical trials of the antioxidant therapy in GD and PD, in addition to other neurodegenerative diseases [40].”
BackgroundMethod
Disorders of glutathione metabolism
Aoyama, K., Kinoshita, C., & Nakaki, T. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813955-4.00065-9 · Cited by 2
Response to "Potential Role of N‐Acetyl Cysteine in the Cysteine Proteome in Parkinson’s Disease?"
Monti, D., & Newberg, A. B. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1713 · Cited by 1
A Comparative study of Posterior cingulate metabolism in Patients with Mild Cognitive Impairment due to Parkinson’s Disease or to Alzheimer’s DiseasePreprint
Huang, M., Cai, X., Zhang, Y., Pu, W., Gao, B., & Yu, H. (2022) · Research Square · doi:10.21203/rs.3.rs-1988963/v1 · Cited by 1
High-frequency, low-intensity pulsed electric field and N-acetylcysteine synergistically protect SH-SY5Y cells against hydrogen peroxide-induced cell damage in vitroPreprint
Hsu, F.-T., Kuo, Y.-Y., & Chao, C. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.11.675733 · Cited by 1
Disorders of Glutathione Metabolism
Aoyama, K., & Nakaki, T. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-410529-4.00061-9
Severely Stressed Astrocytes Adapt to Injury and Still Protect Neighboring Neurons
Gleixner, A. M. (2015)
Evaluation of Glutamatergic Treatment in Reducing Nicotine Seeking Behavior in Rats
Moro, F. (2017) · Open Research Online (The Open University) · doi:10.21954/ou.ro.0000c0ca
Neuroprotection with gluthatione in brain ischemia reperfusion injury
Yabuki, Y., & Fukunaga, K. (2015) · Cerebral Blood Flow and Metabolism (Japanese journal of cerebral blood flow and metabolism) · doi:10.16977/cbfm.26.2_39
Peer Review #1 of "N-acetylcysteine protects against motor, optomotor and morphological deficits induced by 6-OHDA in zebrafish larvae (v0.1)"
(2018) · PeerJ · doi:10.7287/peerj.4957v0.1/reviews/1
Peer Review #1 of "N-acetylcysteine protects against motor, optomotor and morphological deficits induced by 6-OHDA in zebrafish larvae (v0.2)"
(2018) · PeerJ · doi:10.7287/peerj.4957v0.2/reviews/1
The role of selected antioxidants in the development and treatment of Parkinson’s disease
Markowska, D., Malicka, D., Nuszkiewicz, J., & Szewczyk‐Golec, K. (2019) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/01.3001.0013.5252
Pick the Company 企業紹介(第76回 2)株式会社TV・ポータル
平田, 和., & 武居, 邦. (2010) · 衛星&ケーブルテレビ
Cellular Cysteine Network and Neurodegeneration
Pawar, S. H., Gulecha, V., Mahajan, M., Upaganiawar, A. B., & Upasani, C. D. (2020) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-7998-1317-0.ch012
Influences On Monoamine Oxidase Activity In The Brain And Translation Into Major Depressive Disorder
Raitsin, S. (2018) · TSpace (University of Toronto)

Authors: Holmay, M. J., Terpstra, M., Coles, L. D., Mishra, U., Ahlskog, M., Öz, G., Cloyd, J. C., & Tuite, P. J.
Affiliations: University of Minnesota (US)
Cornell University (US)
Corresponding author: Holmay, Mary J.
ORCID: Holmay, Mary J.
Terpstra, Melissa
Coles, Lisa D.
Mishra, Usha
Öz, Gülin
Cloyd, James C.
Tuite, Paul J.
Venue: Clinical Neuropharmacology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2013-07
Volume: 36
Issue: 4
Pages: 103-106
ISSN: 0362-5664 (ISSN-L)
DOI: 10.1097/wnf.0b013e31829ae713
PMC: PMC3934795
OpenAlex: W2010686114
Cited by: 216
References: 29
Citations by year: 2026: 14 · 2025: 14 · 2024: 14 · 2023: 19 · 2022: 20 · 2021: 20 · 2020: 18 · 2019: 12 · 2018: 14 · 2017: 26 · 2016: 15 · 2015: 15 · 2014: 10 · 2013: 2
FWCI: 8.89
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Clinical Neuropharmacology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute of Neurological Disorders and Stroke (U54NS065768, P30NS076408)
National Institute of Biomedical Imaging and Bioengineering (P41EB015894)
National Center for Research Resources (S10RR026783, P41RR008079)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Sulfur Compounds in Biology
Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
Keywords: N-acetylcysteine, glutathione, Parkinson's disease, Gaucher disease, brain glutathione, antioxidant therapy, redox state, neurodegenerative diseases
MeSH terms: Acetylcysteine, Adolescent, Antioxidants, Antiparkinson Agents, Brain, Female, Gaucher Disease, Glutathione, Humans, Infusions, Intravenous, Kinetics, Magnetic Resonance Imaging, Male, Middle Aged, Neurons, Oxidation-Reduction, Parkinson Disease, Up-Regulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

N-acetylcysteine Boosts Brain and Blood Glutathione in Gaucher and Parkinson Diseases

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks